This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
GILD or AMGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. AMGN: Which Stock Is the Better Value Option?
10 Stocks of the S&P 500 ETF Up More Than 20% in Q1
by Sweta Killa
While many stocks in the S&P 500 ETF posted dismal performance in the just-concluded quarter, we discuss some that rose by more than 20%.
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected
by Zacks Equity Research
J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -259.70% and 52.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
by Zacks Equity Research
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation
by Zacks Equity Research
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
by Zacks Equity Research
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
by Zacks Equity Research
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 29.41% and 1.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
by Zacks Equity Research
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
by Zacks Equity Research
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
by Zacks Equity Research
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
by Zacks Equity Research
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.